Alembic Pharmaceuticals
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Alembic Pharmaceuticals is at a pivotal growth juncture, primarily driven by its U.S. generics segment, which is benefiting from strategic product launches, including bosutinib under 180-day exclusivity. Management's recent guidance upgrades reflect confidence in accelerating revenue growth, particularly in the U.S. and international markets. However, the company is also investing heavily in R&D and specialty products, which may pressure margins in the short term. Vista's financial outlook anticipates stable margins and a revenue growth trajectory that exceeds historical performance, supported by these strategic initiatives. The Indian pharmaceutical sector's expansion, bolstered by currency depreciation and a strong pipeline of innovative products, further enhances Alembic's growth prospects. Key opportunities include the scaling of the branded specialty portfolio and geographic diversification, while watchpoints include potential margin volatility and regulatory challenges. Over the next 12-24 months, Alembic's focus on high-value products and operational excellence will be critical in navigating the competitive landscape and achieving its financial targets
Why We Like This Stock
- Accelerating revenue growth driven by successful U.S. generics and strategic product launches
- Management's confidence in achieving breakeven in the branded specialty segment by FY28
- Strong pipeline of innovative products and geographic diversification enhancing long-term growth potential
Things To Watch Out For
- Short-term margin pressures due to increased R&D and marketing investments
- Potential regulatory compliance risks and competitive pricing pressures in the API segment
- Volatility in supply chains and external market conditions could impact operational stability
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 6,229 | 6,672 | 7,345 | 8,296 | 9,088 |
| Profit Before Tax (Cr.) | 629 | 690 | 761 | 879 | 986 |
| PBT Margin | 10.1% | 10.3% | 1036.1% | 10.6% | 10.9% |
| Net Profit (Cr.) | 565 | 584 | 622 | 721 | 804 |
| Earnings Per Share | 28.7 | 29.8 | 31.8 | 36.4 | 40.9 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Deven Choksey | ► Hold | 836 | 05-Aug-2026 |
| HSBC | ► Add | 800 | 08-May-2026 |
| ICICI Securities | ► Add | 875 | 05-Aug-2026 |
Company Overview
Show Company Profile
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.